Biofloris Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 6.00 M
as on 30-10-2024
- Paid Up Capital ₹ 5.70 M
as on 30-10-2024
- Company Age 7 Year, 3 Months
- Last Filing with ROC 31 Mar 2023
- Revenue 11.05%
(FY 2023)
- Profit 94.15%
(FY 2023)
- Ebitda 134.54%
(FY 2023)
- Net Worth 43.28%
(FY 2023)
- Total Assets 29.57%
(FY 2023)
About Biofloris Pharmaceuticals
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 6.00 M and a paid-up capital of Rs 5.70 M, as per Ministry of Corporate Affairs (MCA) records.
Murugesan Chandrasekaran, Dhanasekaran Ravishankar, Balakrishnan Rajaganesan, and Six other members serve as directors at the Company.
- CIN/LLPIN
U33300TZ2017PTC029531
- Company No.
029531
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
28 Sep 2017
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Coimbatore
Industry
Company Details
- Location
Salem, Tamil Nadu, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Biofloris Pharmaceuticals?
Board Members(9)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Murugesan Chandrasekaran  | Director | 28-Sep-2017 | Current |
| Dhanasekaran Ravishankar | Director | 28-Sep-2017 | Current |
| Balakrishnan Rajaganesan | Director | 01-Dec-2017 | Current |
| Muthu Deivasigamani | Director | 01-Dec-2017 | Current |
| Manickam Rajendran | Director | 01-Dec-2017 | Current |
| Rajamanikkam Kandasamy | Director | 01-Dec-2017 | Current |
Financial Performance of Biofloris Pharmaceuticals.
Biofloris Pharmaceuticals Private Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 11.05% increase. The company also saw a substantial improvement in profitability, with a 94.15% increase in profit. The company's net worth Soared by an impressive increase of 43.28%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Biofloris Pharmaceuticals?
In 2023, Biofloris Pharmaceuticals had a public holding of 87.23%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Aishwaryam Speciality Hospital Private LimitedActive 15 years 4 monthsMurugesan Chandrasekaran is a mutual person
Couguar Radhai Nutraceuticals Private LimitedActive 11 months 24 daysMurugesan Chandrasekaran is a mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Biofloris Pharmaceuticals?
Unlock and access historical data on people associated with Biofloris Pharmaceuticals, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Biofloris Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Biofloris Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
